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Abstract
Background: Cardiac-specific troponin detected with the new high-sensitivity assays can be chronically elevated in
response to cardiovascular comorbidities and confer important prognostic information, in the absence of unstable
coronary syndromes. Both diabetes mellitus and coronary artery disease are known predictors of troponin elevation.
It is not known whether diabetic patients with coronary artery disease have different levels of troponin compared
with diabetic patients with normal coronary arteries. To investigate this question, we determined the concentrations
of a level 1 troponin assay in two groups of diabetic patients: those with multivessel coronary artery disease and
those with angiographically normal coronary arteries.
Methods: We studied 95 diabetic patients and compared troponin in serum samples from 50 patients with coronary
artery disease (mean age = 63.7, 58 % male) with 45 controls with angiographically normal coronary arteries. Brain
natriuretic peptide and the oxidative stress biomarkers myeloperoxidase, nitrotyrosine and oxidized LDL were also
determined.
Results: Diabetic patients with coronary artery disease had higher levels of troponin than did controls (median values,
12.0 pg/mL (95 % CI:10–16) vs 7.0 pg/mL (95 % CI: 5.9-8.5), respectively; p = 0.0001). The area under the ROC curve for
the diagnosis of CAD was 0.712 with a sensitivity of 70 % and a specificity of 66 %. Plasma BNP levels and oxidative
stress variables (myeloperoxidase, nitrotyrosine, and oxidized LDL) were not different between the two groups. In
a multivariate analysis, gender (p = 0.04), serum glucose (0.03) and Troponin I (p = 0.01) had independent statistical
significance.
Conclusion: Troponin elevation is related to the presence of chronic coronary artery disease in diabetic patients
with multiple associated cardiovascular risk factors. Troponin may serve as a biomarker in this high-risk population.
Trial registration: http://www.controlled-trials.com Registration number:ISRCTN26970041
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Background
Cardiac-specific troponins (cTn) have received inter-
national endorsement as the standard biomarkers for de-
tection of myocardial injury [1]. To enhance diagnostic
sensitivity, new methods have been developed recently
that can detect very low levels of troponin in the blood
and have resulted in improved diagnostic accuracy [2],
but have, on the other hand, led to loss of specificity:
cTn has become detectable in subjects without acute
myocardial injury [3, 4]. Besides having become detect-
able in subjects without acute heart disease, detectable
cTn is associated with cardiovascular comorbidities and
higher mortality in the general population [5–8] and in
many disease conditions [9, 10].
Assuming that diabetes is a microvascular disease and
therefore contributes to chronic myocite injury [11], sev-
eral mechanisms may contribute to the increased risk of
coronary artery disease (CAD) development [12–14],
such as metabolic factors (advanced glycation end prod-
ucts and lipoprotein abnormalities) [15], coagulation
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abnormalities [16], endothelial dysfunction [17] and higher
levels of oxidative stress [18]. Consistent with these func-
tional alterations, the presence of type 2 diabetes mellitus
was already a known predictor of elevated cardiac tropo-
nin in the general population with the older assays [19].
With the new assays, detection in the general population
has become more common: circulating high sensitivity
troponin T was measurable in 90 % of otherwise healthy
diabetic patients [20]. These elevations are related to car-
diovascular disease and cardiovascular death in diabetic
compared to nondiabetic patients [21].
In patients with chronic CAD, concentrations of high
sensitivity troponin T are higher than that in healthy con-
trols [22, 23] and correlate with the incidence of cardio-
vascular death or heart failure [23, 24] and total mortality
[25]. The extent of CAD measured by the coronary plaque
burden on cardiac computed tomographic angiography
also correlates with high sensitivity troponin T [26].
Therefore, both diabetes mellitus and chronic CAD
are known predictors of elevation of cTn [6, 23]. It is
not known whether diabetic patients with CAD have dif-
ferent levels of cTn compared with diabetic patients with
normal coronary arteries. To investigate this question,
we determined the levels of cTn in two groups of dia-
betic patients: patients with multivessel CAD and those
with angiographically normal coronary arteries.
Methods
Study subjects
The study included patients with type 2 diabetes mellitus
with angiographically documented proximal multivessel
coronary stenosis of >70 %, these patients had normal
ventricular function and received optimal medical treat-
ment without coronary revascularization. This group of
patients with multivessel CAD was compared to patients
with type 2 diabetes mellitus and angiographically nor-
mal coronary arteries identified by angiogram or coron-
ary tomography, also with normal ventricular function.
The following were considered as exclusion criteria:
smoking, left ventricular dysfunction, atrial fibrillation, un-
controlled hypertension (systolic blood pressure greater
than 180 mm Hg and/or diastolic blood pressure greater
than 100 mm hg), chronic kidney disease (GFR = 45-
59 mL/min or less), hepatic impairment, hypothyroidism,
recent surgery, and degenerative musculoskeletal disease.
The study conformed to the guidelines set out in the
Declaration of Helsinki and was approved by the Ethics
Committee of the University of São Paulo Medical School.
All participants gave written informed consent for partici-
pation in the study.
Patients were instructed to interrupt statin use 45 days
before blood collection. Blood samples were collected
after a 12-h fast. After centrifugation, plasma was ali-
quoted and stored at −70 °C until analysis.
Laboratory analysis
Glucose, glycated hemoglobin (HbA1c), total cholesterol,
and triglycerides were determined from serum samples
after a 12-h fast, by using specific kits in the automated
equipment Dimension RxL (Siemens Healthcare, Newark,
USA). HDL-cholesterol was measured by a homogeneous
enzymatic colorimetric method specific for Dimension
RxL. LDL-cholesterol was estimated using the Friedewald
formula.
Cardiac troponin I
Cardiac troponin-I was determined using the ADVIA
Centaur®TnI-Ultra kit (Siemens Healthcare Diagnostics,
NY, USA) in the automated equipment of the same manu-
facturer. The test is an immunoassay that uses a direct
chemiluminescence technology and constant amounts of
two monoclonal antibodies. An increased TnI concentra-
tion is defined as a value exceeding the 99th percentile of
a normal reference population. According to the manufac-
turers, the detection limit is 0.006 ng/mL, the population
reference value at the 99th percentile is <0.04 ng/mL, and
the coefficient of variation is <10 % at this 99th percentile.
Siemens Centaur ultra is not considered a high-
sensitivity assay, instead, it is designated as a contempor-
ary or level 1 assay. The new troponin assays are defined
by their ability to detect troponin above the limit of detec-
tion in normal individuals and classified according to the
percentage of normal individuals detected in four categor-
ies: level 1 corresponds to <50 % of measurable normal
values, level 2: 50-75 %, level 3: 75-95 %, and level 4:
≥95 %. Only levels two to four are considered high-
sensitivity assays [27]. We have used the designation level
1 assay or the general designation: cardiac troponin.
Brain natriuretic peptide and oxidative and myocardial
stress biomarkers
The oxidative stress biomarkers myeloperoxidase and nitro-
tyrosine were determined using solid-phase enzyme linked
immunosorbent assays (Hycult, Uden, The Netherlands).
Oxidized LDL was determined using a competitive enzyme
linked immunosorbent assay (Mercodia, Uppsala, Sweden).
Brain natriuretic peptide (BNP) concentrations were
determined through chemiluminescence immunoassay
(Siemens Healthcare Diagnostics, NY, USA).
Statistical analysis
Data were analyzed using MedCalc (version 12). Median
and interquartile ranges were used to show skewed
troponin values. The categorical variables are pre-
sented as absolute and relative (%) values. A two-tailed
p value <0.05 was considered significant. Baseline char-
acteristics of patients were examined in coronary
artery disease and control groups. The Student’s t test
was used for continuous variables and the chi-squared
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test or Fisher’s exact test for categorical variables. The
Mann–Whitney test was used for nonparametrical var-
iables. Multivariate analysis was performed using logis-
tic regression, the model being composed of variables
with p < 0.20 in the univariate analysis.
Results
Between January 2011 and March 2012, 95 diabetic pa-
tients were included in this study. Fifty patients had
chronic coronary artery disease while the remaining 45
patients, the control group, had angiographically normal
arteries. The clinical and laboratory characteristics of
study participants are shown in Table 1. There were no
significant differences among the two groups. Patients
with CAD had higher concentrations of total cholesterol
and LDL cholesterol.
Plasma BNP concentrations and oxidative stress vari-
ables (myeloperoxidase, nitrotyrosine, and oxidized LDL)
are shown in Table 2. Concentrations were not signifi-
cantly different between the two groups.
As shown in Fig. 1, diabetic patients with CAD had
higher levels of troponin than did controls: median
values, 12.0 pg/mL (95 % CI:10–16 pg/mL) vs 7.0 pg/mL
(95 % CI: 5.9-8.5 pg/mL), respectively; p = 0.0001. The
area under the ROC curve for the diagnosis of CAD,
shown in Fig. 2 was 0.712 with a sensitivity of 70 % and
a specificity of 66 %. In the multivariate analysis per-
formed and shown in Table 3, gender (p = 0.04), Tropo-
nin I (p = 0.01), and serum glucose with a negative
correlation coefficient (p = 0.03) had independent statis-
tical significance.
Discussion
In the present study, we evaluated cTn levels in 95 dia-
betic patients with preserved ventricular function, in the
absence of an acute coronary syndrome. We found that
concentrations of cTn were significantly higher (p =
0.0001) in diabetic patients with stable coronary artery
disease. This finding is consistent with that in other
studies that have also shown elevation of cTn in stable
coronary artery disease patients [22, 23, 26, 28], but
these studies were not specifically designed to test this
hypothesis in diabetic patients. The specific contribution
of our study is to confirm the association of cTn elevation
with CAD in diabetic patients with multiple associated
cardiovascular risk factors, demonstrating that cTn is also
a useful biomarker in patients with diabetes mellitus. This
conclusion is not straightforward, because diabetes melli-
tus “per se” is associated with an elevation in cTn concen-
trations [20, 21]. Although a study that investigated high
sensitivity Troponin T concentrations in diabetic patients
has shown an association with age, gender, and renal func-
tion but not with the presence of CAD [20]. In another
study that used high sensitivity Troponin I, and a largerTable 1 Patients characteristics
Characteristica CAD (n = 50) Controls (n = 45) P Values
Age, mean ± SD, y 63.3 ± 8.3 61.4 ± 9.4 0.34
Female n (%) 20 (42) 26 (60,5) 0.07
Hypertension n (%) 40 (83) 36 (84) 0.42
Waist, mean ± SD (cm) 103 ± 13 108 ± 17 0.09
BMI, mean ± SD, Kg/m2 30.6 ± 6.3 32.4 ± 6.7 0.22
Total Cholesterol (mg/ dL) 216 ± 45 193 ± 33 0.01
LDL Cholesterol (mg/dL) 142 ± 41 124 ± 31 0.03
HDL Cholesterol (mg/dL) 37 ± 8 39 ± 8 0.47
Triglycerides (mg/dL) 173 ± 75 163 ± 70 0.55
Serum Glucose (mg/dL) 124 ± 37 134 ± 32 0.18
Hemoglobin A1C(mg/dL) 7.2 ± 1.8 7.3 ± 1.6 0.61
Insulin use n (%) 12 (25) 11 (26) 0.43
Duration of diabetes, y 9.9 ± 9.7 7.07 ± 6.9 0.16
aCAD indicates coronary artery disease, BMI indicates body mass index,
LDL cholesterol indicates low density lipoprotein, HDL cholesterol
indicates High density lipoprotein, Hemoglobin A1C indicates
glycated hemoglobin
Table 2 BNP and oxidative stress variables
Variable CAD Controls P Values
BNP (n = 78),
median values (n), pg/mL
37,0 (34) 28.5 (44) 0.08
Nitrotyrosine (n = 68),
median values (n), nm/mL
27.9 (36) 28.7 (32) 0.77
Myeloperoxidase (n = 68),
median values, ng/mL
33.0 (37) 27.0 (31) 0.96
Oxidized LDL (n = 71),
median values (n), mU/L
14.8(35) 11.2(36) 0.09
BNP indicates B-type natriuretic peptide, Oxidized LDL indicates oxidized
low-density lipoprotein
Fig. 1 hsTroponinI concentrations in CAD and control groups.
Diabetic patients with coronary artery disease had higher levels of
troponin than did controls (median values, 12.0 pg/mL (95 % CI:10–16)
vs 7.0 pg/mL (95 % CI: 5.9-8.5), respectively; p = 0.0001)
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number of patients with longer follow-up, troponin I
elevation was a predictor of CAD [29]. These two stud-
ies did not include multivessel coronary artery disease
patients. It is possible that troponin release is related to
more diffuse coronary disease, which is a prognostic
factor in coronary artery disease [30], and is considered
more common among diabetic patients with triple ves-
sel disease [31], which is the group of patients included
in our study sample.
Meta-analyses suggest that a previous generation of
cardiac troponins I and T had comparable diagnostic
and prognostic performance in most clinical settings
[32]. The new assays have detected different biological
characteristics in high-sensitivity troponin I and T that
may be clinically relevant. In a study that compared both
biomarkers in a large number of patients, the correlation
between the concentrations of the two biomarkers was
only of moderate strength. Elevated concentrations of
troponin I, but not troponin T, were significantly and in-
dependently associated with both prior and the inci-
dence of subsequent acute myocardial infarction [24]. In
our study, we have also used troponin I, which again,
has shown a good correlation with the presence of CAD.
Studies with a larger number of patients comparing the
two types of troponin would be necessary to determine
which one correlates better with the presence of CAD.
Until now, evidence points to the use of troponin I to
this purpose.
The reason for the discrepancy between the concen-
trations of the two types of troponin is not known, and
the mechanism that causes troponin release in patients
with coronary artery disease is still under investigation.
Many hypotheses have been proposed, including transi-
ent, clinically silent ischemic episodes and small vessel
occlusion, inflammatory processes, cardiomyocyte apop-
tosis [33], leakage of a cytoplasmatic pool of troponins
[34], and plaque microembolization, because the con-
centrations of high-sensitivity troponin T are related to
noncalcified plaque burden and vascular remodeling
[28]. In our study, cTn concentrations in diabetic pa-
tients without CAD were low and close to the limit of
detection of the method used. This result suggests that
troponin release is related to the presence of coronary
atherosclerosis and not to any other kind of damage to
the heart caused by diabetes mellitus.
In the sample studied, total cholesterol and LDL chol-
esterol concentrations were higher among CAD patients,
confirming a finding that is well established among differ-
ent populations [35]. One unanticipated finding is that
serum glucose and hemoglobin A1C concentrations were
not different between CAD patients and the control
group. However, in the multivariate analysis, serum glu-
cose (with a negative correlation coefficient) was related to
Fig. 2 ROC curve for the diagnosis of CAD. The area under the ROC
curve for the diagnosis of CAD was 0.712 with a sensitivity of 70 %
and a specificity of 66 %
Table 3 Multiple regression
Independent variables Coefficient Std. Error rpartial t P
(Constant) −0.04849
Waist −0.002267 0.003964 −0.07906 −0.572 0.5699
Gender 0.2735 0.1304 0.2794 2.098 0.0408
TC 0.004189 0.002269 0.2480 1.846 0.0706
LDL −0.00007268 0.002797 −0.003604 −0.0260 0.9794
Glucose −0.003659 0.001730 −0.2815 −2.115 0.0392
Duration_of_diabetes 0.01060 0.008039 0.1799 1.319 0.1930
BNP −0.001938 0.002445 −0.1092 −0.792 0.4317
Ox_LDL −0.0003638 0.01383 −0.003649 −0.0263 0.9791
Tropo 0.02919 0.01135 0.3359 2.572 0.0130
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CAD in diabetic patients. Hyperglycemia is a risk factor
for CAD in epidemiological studies [36]. The unexpected
finding of a negative correlation between serum glucose
and CAD is probably related to a bias in the study sample,
in which the control group had slightly worse, but not sta-
tistically significant, glycemic control. Another factor that
could explain the lack of difference in glycemic control
among CAD and controls is that macrovascular complica-
tions do not correlate linearly with HbA1c [37] and the
presence of prior vascular disease is one of the predictors
of poor cardiovascular outcomes after treatment intensifi-
cation for insufficient glycemic control [38]. As regards
gender, male sex is a well-known risk factor for CAD [39]
and also correlated with CAD, in the multivariate analysis,
in this study.
Limitations
The troponin kit used in this study is not among the
most sensitive tests available [27], nevertheless, the sen-
sitivity was high enough to show a significant difference
between the two groups studied.
Other limitations of this study deserve comment. First,
the number of patients is relatively small, and the find-
ings need to be confirmed in larger studies. Second, this
is a case–control study that cannot provide information
on prognostic implications of subjects with elevated
high-sensitivity troponin.
Conclusion
Troponin elevation is related to the presence of chronic
coronary artery disease in diabetic patients with multiple
associated cardiovascular risk factors. Troponin may
serve as a biomarker in this high-risk population.
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